dc.creator | Vasileiadis G.K., Dardiotis E., Mavropoulos A., Tsouris Z., Tsimourtou V., Bogdanos D.P., Sakkas L.I., Hadjigeorgiou G.M. | en |
dc.date.accessioned | 2023-01-31T10:27:27Z | |
dc.date.available | 2023-01-31T10:27:27Z | |
dc.date.issued | 2018 | |
dc.identifier | 10.1007/s13317-018-0109-x | |
dc.identifier.issn | 20380305 | |
dc.identifier.uri | http://hdl.handle.net/11615/80439 | |
dc.description.abstract | Current clinical experience with immunomodulatory agents and monoclonal antibodies in principle has established the benefit of depleting lymphocytic populations in relapsing–remitting multiple sclerosis (RRMS). B and T cells may exert multiple pro-inflammatory actions, but also possess regulatory functions making their role in RRMS pathogenesis much more complex. There is no clear correlation of Tregs and Bregs with clinical features of the disease. Herein, we discuss the emerging data on regulatory T and B cell subset distributions in MS and their roles in the pathophysiology of MS and its murine model, experimental autoimmune encephalomyelitis (EAE). In addition, we summarize the immunomodulatory properties of certain MS therapeutic agents through their effect on such regulatory cell subsets and their relevance to clinical outcomes. © 2018, The Author(s). | en |
dc.language.iso | en | en |
dc.source | Autoimmunity Highlights | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056457866&doi=10.1007%2fs13317-018-0109-x&partnerID=40&md5=f4df0f52b5f436fef4f1719f6e911d35 | |
dc.subject | alemtuzumab | en |
dc.subject | epitope | en |
dc.subject | fingolimod | en |
dc.subject | fumaric acid dimethyl ester | en |
dc.subject | gamma interferon | en |
dc.subject | glatiramer | en |
dc.subject | immunoglobulin G4 | en |
dc.subject | interleukin 10 | en |
dc.subject | interleukin 12p35 | en |
dc.subject | interleukin 15 | en |
dc.subject | interleukin 16 | en |
dc.subject | interleukin 17 | en |
dc.subject | interleukin 1beta | en |
dc.subject | interleukin 23 | en |
dc.subject | interleukin 27 | en |
dc.subject | interleukin 35 | en |
dc.subject | lymphotoxin | en |
dc.subject | lymphotoxin beta | en |
dc.subject | natalizumab | en |
dc.subject | ocrelizumab | en |
dc.subject | ofatumumab | en |
dc.subject | programmed death 1 ligand 1 | en |
dc.subject | rituximab | en |
dc.subject | teriflunomide | en |
dc.subject | thrombospondin | en |
dc.subject | tocilizumab | en |
dc.subject | tumor necrosis factor | en |
dc.subject | vitamin D | en |
dc.subject | apoptosis | en |
dc.subject | blood brain barrier | en |
dc.subject | CD4 lymphocyte count | en |
dc.subject | cell differentiation | en |
dc.subject | cerebrospinal fluid | en |
dc.subject | clinical outcome | en |
dc.subject | clinical trial (topic) | en |
dc.subject | dendritic cell | en |
dc.subject | environmental factor | en |
dc.subject | epigenetics | en |
dc.subject | experimental autoimmune encephalomyelitis | en |
dc.subject | flow cytometry | en |
dc.subject | heredity | en |
dc.subject | human | en |
dc.subject | immune response | en |
dc.subject | immunomodulation | en |
dc.subject | inflammation | en |
dc.subject | mouse | en |
dc.subject | multiple sclerosis | en |
dc.subject | nonhuman | en |
dc.subject | phenotype | en |
dc.subject | priority journal | en |
dc.subject | protein expression | en |
dc.subject | regulatory B lymphocyte | en |
dc.subject | regulatory T lymphocyte | en |
dc.subject | relapse | en |
dc.subject | remission | en |
dc.subject | Review | en |
dc.subject | Springer-Verlag Italia s.r.l. | en |
dc.title | Regulatory B and T lymphocytes in multiple sclerosis: friends or foes? | en |
dc.type | other | en |